Overview Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) Status: Recruiting Trial end date: 2022-12-01 Target enrollment: Participant gender: Summary This study will assess the safety and efficacy of ARQ-154 foam vs vehicle applied once daily for 8 weeks by subjects with scalp and body psoriasis. Phase: Phase 3 Details Lead Sponsor: Arcutis Biotherapeutics, Inc.